The simulated intravascular and extravascular kinetics of cefotaxime were studied in an in vitro model to evaluate the effect of antibiotic protein binding in the "intravascular" and "extravascular" space. Intravascular fluid consisted of either phosphate-buffered saline, which has no cefotaxime binding, or 3% bovine albumin, which has 63% cefotaxime binding. Extravascular spaces were filled with phosphatebuffered saline, 1.5% bovine albumin (46.6% cefotaxime binding), or 3% bovine albumin. Cefotaxime (80 mg per dose) was infused every 3 h for eight doses, and intravascular and extravascular drug concentrations were measured after doses one and eight. The corresponding intravascular and extravascular spaces were at (phosphate-buffered saline) or approaching (3% bovine albumin) equilibrium by dose eight. There were marked differences in drug concentrations achieved in the various extravascular spaces, but all could be explained on the basis of differing amounts of albumin present and the resultant differences in cefotaxime binding.
The simulated intravascular and extravascular kinetics of cefotaxime were studied in an in vitro model to evaluate the effect of antibiotic protein binding in the "intravascular" and "extravascular" space. Intravascular fluid consisted of either phosphate-buffered saline, which has no cefotaxime binding, or 3% bovine albumin, which has 63% cefotaxime binding. Extravascular spaces were filled with phosphatebuffered saline, 1.5% bovine albumin (46.6% cefotaxime binding), or 3% bovine albumin. Cefotaxime (80 mg per dose) was infused every 3 h for eight doses, and intravascular and extravascular drug concentrations were measured after doses one and eight. The corresponding intravascular and extravascular spaces were at (phosphate-buffered saline) or approaching (3% bovine albumin) equilibrium by dose eight. There were marked differences in drug concentrations achieved in the various extravascular spaces, but all could be explained on the basis of differing amounts of albumin present and the resultant differences in cefotaxime binding.
We have previously reviewed the implications of antibiotic binding to serum and tissue proteins, and in that review we discussed how binding influences the measured drug concentration in the intravascular and extravascular spaces and how protein binding affects antibiotic distribution (6) . We have stressed that for correct interpretation of antibiotic serum levels and penetration into extravascular sites, the antibiotic protein binding in both the intravascular and extravascular compartments needs to be known.
The purpose of this report is to demonstrate, in an in vitro kinetic model, that antibiotic protein binding alone alters the measured drug levels at simulated "intravascular" and "extravascular" sites and that without knowledge of antibiotic binding at all sites under study, the apparent differences in drug penetration are difficult to interpret.
MATERIALS AND METHODS
In vitro kinetic model. Intravascular and extravascular kinetics of cefotaxime were simulated by using a modification of the in vitro kinetic model of Murakawa et al. (4) , which has been previously described (11, 12) . Three sterile chambers were assembled: chamber A held several liters of gterile antibiotic-free fluid which supplied the system with fresh diluent, chamber B (intravascular test chamber) held 500 ml of fluid, and chamber C (a modulating chamber which simulates a portion of the extravascular space) held 30 ml of fluid. The antibiotic-free fluid was either phosphate-buffered saline (PBS; pH 7.2) for the nonprotein diluent or 3.01% (g/100 ml) bovine albumin (Armour Pharmaceuticals, Phoenix, Ariz.) in PBS as the protein-based diluent. Bovine serum albumin was chosen to maintain reasonable costs, as large volumes of this fluid are required for these experiments. Fluid was pumped from chamber A to chamber B and from chamber B to chamber C by a peristaltic pump at a flow rate of 13 ml/min. Chambers B and C, with an air-tight seal, created a passive flow back from chamber C to chamber B and then out of chamber B to waste. Chambers B and C were constantly mixed with a magnetic stirrer to ensure homogenous samples. Eight 10-ml extravascular sampling spaces were suspended in chamber B, with each space consisting of 8 cm of Visking tubing (diameter, 1.57 cm; Union Carbide), which was tied in a knot at one end and corked at the opposite end. The spaces were suspended such that the Visking tubing was submerged in fluid and the top of the cork was just above the fluid level. Two spaces contained PBS, three spaces contained 1.5% bovine albumin in PBS, and three spaces contained 3.0%o bovine albumin in PBS. These extravascular spaces were sampled with a small polyethylene tube which was passed through the cork. Two spaces of each protein concentration were sampled at each time point. Intravascular chamber samples were collected from the exit drain of chamber B at each time point.
Antibiotic administration and specimen collection. Cefotaxime (Hoechst-Roussel Pharmaceuticals, Inc., Somerville, N.J.) was infused by means of a Harvard pump into an access port in the tubing entering intravascular chamber B from chamber A. Cefotaxime (80 mg) was infused over a 30-min time interval, in a volume of 2.29 ml of PBS, every 3 h for a total of eight doses per experiment. Six experiments were carried out, three with PBS as the intravascular diluent and three with 3.0% bovine albumin in PBS. Samples were taken during doses one and eight. Extravascular spaces were aspirated at 0, 30, 45, 60, 120, and 180 min after the start of doses one and eight. Samples were obtained from chamber B at 0, 10, 20, 30, 45, 60, 90, 120, and 180 min after the start of doses one and eight.
Cefotaxime assay. Cefotaxime was assayed by a highpressure liquid chromatographic technique (2) with a Varian 5020 chromatograph and with a Varichrom variable wavelength detector set at 270 nm. Albumin-based samples were prepared with anion-exchange columns (2) to remove the albumin before injection; PBS-based samples were injected without preparation. Albumin sample eluates (100 pl) or PBS samples (10 pl) were injected onto a Waters ,uBondapak column for analysis. Sample concentrations were calculated by an external standard method by using CDS llL integrated peak areas. All samples were chromatographed twice. Calculations. The area under the curve (AUC) was measured for the simulated intravascular compartment for both protein-containing and protein-free portions of the experiment, as well as for all extravascular chamber sites after doses one and eight, with a compensating polar planimeter.
The actual B point, or theoretical true peak concentration of drug in the intravascular space, was determined graphically on semilogarithmic paper from the 1B, or elimination phase, of intravascular cefotaxime and by least-squares regression analysis. Calculated B points (Bc) were determined from the equation (7):
where A is the total drug administered in a given dose; bs is the bound fraction of drug (percent bound + 100) in each space, s;fi is the free fraction of drug (percent free + 100) in the intravascular space, i; fs is the free fraction of drug in each space, s; and V5 is the volume of each space, s.
Equilibrium between the intravascular and the extravascular spaces was defined as the time when the extravascular AUC was within 90% of the intravascular AUC.
Prediction of extravascular concentrations of cefotaxime, taking into account the influence of protein binding in both the intravascular and extravascular spaces, is given by the equation (6) 
RESULTS
The results of the protein-binding experiment are given in Table 1 . The protein binding of cefotaxime increased from 20.4 to 87% with increasing concentration of albtimin, as was anticipated. There was less than a 10% change in protein content in the extravascular spaces after 24 h. This is consistent with our description of this model in vivo where small amounts of albumin were found to enter the chambers at 24 h (5). This did not significantly affect cefotaxime protein binding, and therefore, changes were not further considered in the B-point calculations.
The in vitro curves for the intravascular 3.0% albumin run are shown in Fig. 1 , and curves for the intravascular PBS run are shown in Fig. 2 . The intravascular half-life for both curves is 40 min. The AUCs for each experiment are given in Table 2 . By dose eight, the calculated AUC offree (nonpro- tein-bound) drug in each extravascular space was -90% of the AUC of free antibiotic for the corresponding intravascular space. The actual and calculated B point for the intravascular 3.0% albumin and PBS studies are given in Table 3 . The actual B points are calculated from both doses one and eight, as there was no appreciable cefotaxime accumulation in the intravascular space.
The predicted and actual cefotaxime concentrations in the extravascular spaces at equilibrium (dose eight) are shown in Table 4 .
DISCUSSION
The assessment of antibiotic penetration into various extravascular tissues and fluids, as well as directly into cells, continues to be an area of extensive interest (1, 10) . The current in vitro study exemplifies the need for determination of drug protein binding in both the intravascular and extravascular compartments, which on the cellular scate are represented by extracellular and intracellular spaces. Figure  2 illustrates how protein binding alone in an extravascular space can appear to actively transport and concentrate drug when compared with an intravascular space with little or no antibiotic protein binding. This is particularly evident in the unphysiological situation of intravascular PBS and extravascular 1.5 and 3.0% albumin (Table 2) which demonstrate extravascular to intravascular AUC ratios of 178 and 224%, respectively. However, when the effect of extravascular protein binding is considered, the AUC offree drug for each extravascular space (at dose eight) is -90% the AUC of free drug for the corresponding intravascular spaces, and the drug concentrations achieved are readily explainable and should be anticipated (Table 4) .
This study also demonstrates how extravascular antibiotic protein binding influences the drug concentrations within the intravascular space. Figures 1 and 2 have achieved considerably different intravascular peak cefotaxime levels. The equation used for prediction of B points (Table 3) illustrates that protein binding in both intravascular and extravascular compartments needs to be considered when accurate prediction and evaluation of pharmacokinetics is desired. Our extravascular compartment was only 110 ml (chamber C plus 
